Novo Nordisk A/s

Dr. Reddy's Laboratories, Incorporated

Other

Helle Weibel

Thyge Borup Hjorth

Svend Treppendahl

Tina Meinertz Andersen

Scott E McGraw

Klaus Snej Jensen

Jo Slashedrgen Svensson

Peter Bonne Eriksen

Lars Nygaard

The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiadiazolidine-2,4-dione as active ingredient.

Pharmaceutical composition and the process for its preparation

The present invention provides a new stable pharmaceutical composition containing 5-&lsqb;&lsqb;4-&lsqb;3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl&rsqb;methoxy&rsqb;phenylmethyl&rsqb;thiazolidine-2,4-dione as active ingredient.

Therapeutically effective amounts of a 3,4-diarylchroman can be administered transdermally by incorporation of the 3,4-diarylchroman in a matrix or liquid reservoir patch suitable for transdermal delivery, which matrix or liquid reservoir patch optionally contains hydrophobic and/or hydrophilic vehicle(s).

Transdermal delivery of 3,4-diarylchromans

Pharmaceutical composition containing tiagabine hydrochloride and the

A transdermal delivery system containing tiagabine or its pharmaceutically acceptable salts or esters is disclosed. The delivery system is useful in the treatment of epilepsy.

Transdermal delivery of tiagabine

Growing community of inventors

Hillerød, Denmark

Helle Weibel